Antibody Information

General Information of This Antibody

Antibody ID	ANI0UXZFW
Antibody Name	Anti-ANTXR2 mAb H8R23
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Anthrax toxin receptor 2 (ANTXR2)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

H8R23-DT3C [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.90% (Day 4)	High ANTXR2 expression (ANTXR2+++)
Method Description	The H8R23 mAb, or control IgG, and DT3C were incubated at room temperature for 30 min to generate a mAb-DT3C conjugate. Each conjugate theoretically consists of one mAb molecule (150 kDa) and two DT3Cs (140 kDa). Hs-746 T cells were seeded and incubated in the presence of the H8R23-DT3C conjugates or control IgG-DT3C conjugates (03 ug/mL each) for 96 h, then their viability and level of apoptosis were determined as described above. Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	Hs 746.T cells		CVCL_0333

References

Ref 1	Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations. Exp Cell Res. 2022 Apr 15;413(2):113078.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.